Ambros Therapeutics launches with $125M to advance neridronate, a non-opioid therapy for CRPS-1. See how this Phase 3-ready ...

Clinical trials continue to shape metastatic breast cancer treatment, making therapies safer, more tolerable, and more ...

Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...

To be accepted into a clinical trial, all potential participants must meet the "eligibility criteria" by having similar ...

Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.

Ultragenyx Pharmaceutical Inc. sank after the company’s experimental drug for a rare genetic bone disease failed to meet the ...

Northwell Health and The START Center for Cancer Research held a ceremonial ribbon-cutting to unveil Northwell-START New York-Long Island, which reflects a $5.7 million investment for a 10,000-square ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow ...

Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results ...

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.